{"id":"NCT01142089","sponsor":"Cosmo Technologies Ltd","briefTitle":"Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05-27","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2010-06-11","resultsPosted":"2018-04-10","lastUpdate":"2018-06-08"},"enrollment":264,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Traveler's Diarrhea"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rifamycin SV MMX","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rifamycin SV MMX","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.","primaryOutcome":{"measure":"Time to Last Unformed Stool (TLUS)","timeFrame":"24 hours","effectByArm":[{"arm":"Placebo","deltaMin":37.4,"sd":null},{"arm":"Rifamycin SV MMX","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["Guatemala","Mexico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Headache","Diarrhoea","Diarrhoea infectious","Constipation","Dysmenorrhoea"]}}